TLR4 and myeloid neoplasm: As it has been reported that MSCs of myeloid neoplasms can be therapeutically targeted using epigenetic drugs such as azacytidine (AZA) [43], we finally treated HS-5 stromal cells for 72 h with AZA to evaluate its effect onto mH2A1.1/TLR4 axis.